Britain’s AstraZeneca said Thursday that “good data has come so far” about its vaccine for Covid-19, which is already in large-scale human trials and widely regarded as the favorite in the race for a vaccine against the disease. of the coronavirus.
“Vaccine development is progressing well. We have had good data so far. We need to show efficacy in the clinical program, but so far so good, “Chief Executive Pascal Soriot said in a media call.
Click here for full Covid-19 coverage
AstraZeneca has already reached agreements with countries to make more than 2 billion doses of its Covid-19 vaccine, developed in collaboration with the University of Oxford, and says it could be approved by the end of this year.
The company has had a busy few months: It took over the development of the Covid-19 injection, received billions in government funding, signed various supply deals, and even went through mega-merger speculation, all while marching on its core business.
There are no approved vaccines for the disease caused by the new virus, but the AstraZeneca vaccine is widely considered the top candidate after early-stage human trial results showed that it was safe and produced an immune response.
The drugmaker, Britain’s most valuable listed company, also announced second-quarter results that beat its sales and earnings estimates, thanks to strong sales of a diverse line of products.
Among medications with better-than-expected revenue, sales of the Symbicort respiratory drug increased 12% to $ 653 million, approximately $ 90 million above consensus, while revenue from the cancer drug Lynparza increased 62% to $ 554 million.
Newer diabetes, heart disease and cancer drugs, including best-selling lung cancer drug Tagrisso, performed well in the quarter and AstraZeneca is on track for the third consecutive year of growth.
It held its outlook for 2020 on Thursday, and its shares rose approximately 3% to £ 88.6 after product sales of $ 6.05 billion in the three months to June topped the $ 6.01 billion consensus. The figure excludes mooring payments.
Basic earnings of 96 cents per share exceeded analyst expectations of 93 cents. Total revenue increased 11%.
.
